Cat. No. | Product name | CAS No. |
DC8401 |
BI-847325
Featured
BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1. |
1207293-36-4 |
DC7086 |
BIIB021(CNF2024)
Featured
BIIB021(CNF2024) is an orally available, fully synthetic small-molecule inhibitor of HSP90 with Ki and EC50 of 1.7 nM and 38 nM, respectively. |
848695-25-0 |
DC5154 |
BKM120 (NVP-BKM120, Buparlisib)
Featured
BKM120 is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. |
944396-07-0 |
DC4196 |
Bleomycin Sulfate
Featured
Bleomycin sulfate (Blenoxane) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells. |
9041-93-4 |
DC10530 |
BLU-285 (Avapritinib)
Featured
BLU-285 is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V. |
1703793-34-3 |
DC10092 |
BLU554(Fisogatinib)
Featured
BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor. |
1707289-21-1 |
DC11479 |
BLU-667 (Pralsetinib)
Featured
BLU-667 (Pralsetinib) is a highly potent, selective, next generation RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion. |
2097132-94-8 |
DC8280 |
BLU-9931
Featured
BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM). |
1538604-68-0 |
DC8103 |
BLZ-945
Featured
BLZ945 is a highly selective and brain-penetrant inhibitor of CSF1R with IC50 of 1 nM; >3200-fold higher than its affinity for other kinases. |
953769-46-5 |
DC3105 |
BMS-599626 (AC480)
Featured
BMS-599626 (AC480) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, respectively. |
714971-09-2 |
DC3126 |
BMS754807
Featured
BMS-754807 is a potent and reversible inhibitor of IGF-1R/IR family kinases, inhibits IGF-1R, IR, Met, TrkA and TrkB with IC50 of 1.8 nM, 1.7 nM, 5.6 nM, 7.4 nM and 4.1 nM, respectively. |
1001350-96-4 |
DC9638 |
BMS-794833
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7/15 nM; also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. |
1174046-72-0 |
DC11862 |
BMS-906024
BMS-906024 is a highly potent, selective inhibitor of γ-secretase mediated signaling of Notch1/2/3/4 receptors with IC50 of 1.6/0.7/3.4/2.9 nM, respectively. |
1401066-79-2 |
DC4175 |
BMS-911543
Featured
BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, approximately 350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. |
1271022-90-2 |
DC10609 |
BMS-986158
Featured
BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins. |
1800340-40-2 |
DC10131 |
BMS-986205(Linrodostat)
Featured
BMS-986205 is an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic activity, alone and in combination with nivolumab in advanced cancers in a phase 1/2a trial |
1923833-60-6 |
DC1027 |
Bortezomib (Velcade,MG-341,PS-341)
Featured
Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM. |
179324-69-7 |
DC2019 |
Brivanib (bms-540215)
Featured
Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively. |
649735-46-6 |
DC7378 |
BSI-201
BSI-201 (Iniparib; NSC-746045) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). |
160003-66-7 |
DC10864 |
C188-9
Featured
C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors. |
432001-19-9 |
DC10648 |
CA4948-Analog
Featured
CA4948-Analog is an analog of Emavusertib. It has similar property to CA-4948, which is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It was reported in patent WO 2015104688. Emavusertib, also known as CA-4948 i |
1801343-74-7 |
DC4186 |
Cabazitaxel
Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid. |
183133-96-2 |